Testing NM6603 in advanced solid tumors
Part of Cancer clinical trials.
This study tests an experimental oral drug called NM6603 in people with advanced solid tumors, especially colorectal cancer or triple-negative breast cancer. It aims to find a safe dose and see how the drug works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colorectal cancer, triple-negative breast cancer, or another solid tumor that has spread
- Standard treatments have stopped working, you can't tolerate them, or none are available for your cancer
- You have at least one tumor that can be measured on a scan
- You are between 18 and 75 years old, weigh at least 99 pounds (men) or 88 pounds (women), and are in fairly good health (ECOG score 0 or 1)
- Your heart, liver, kidneys, and blood counts are working well enough based on blood tests
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study and for 6 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
This trial tests a new drug called AMT-676 in people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers like colorectal, stomach, or pancreatic cancer.
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
This trial tests a new experimental drug for people with advanced solid tumors that have not responded to standard treatments. It aims to find a safe dose and see if the drug can shrink tumors.
This Phase 1 trial studies how a new medicine (KC1036) works and how safe it is for people with advanced solid cancers that have grown despite standard treatments. It may help future patients by showing whether the drug can control cancer in difficult-to-treat cases.
This trial tests a new drug, GSK5460025, alone or with other cancer treatments, for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help those whose cancer has a specific genetic feature (dMMR or MSI-H) or who have not responded to standard treatments.
Hear when a new Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.